| Product Code: ETC6751020 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Overview |
3.1 China Country Macro Economic Indicators |
3.2 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, 2021 & 2031F |
3.3 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market - Industry Life Cycle |
3.4 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market - Porter's Five Forces |
3.5 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume Share, By Drugs Type, 2021 & 2031F |
3.6 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume Share, By Indication Type, 2021 & 2031F |
3.7 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.8 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of cancer in China |
4.2.2 Growing awareness about PARP inhibitors for cancer treatment |
4.2.3 Technological advancements in the development of PARP inhibitors |
4.3 Market Restraints |
4.3.1 Stringent regulatory approval processes for new drugs in China |
4.3.2 High cost associated with PARP inhibitors |
4.3.3 Limited reimbursement policies for PARP inhibitors in China |
5 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Trends |
6 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By Types |
6.1 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By Drugs Type |
6.1.1 Overview and Analysis |
6.1.2 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Drugs Type, 2021- 2031F |
6.1.3 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Talazoparib, 2021- 2031F |
6.1.4 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Veliparib, 2021- 2031F |
6.1.5 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Olaparib, 2021- 2031F |
6.1.6 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.2 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By Indication Type |
6.2.1 Overview and Analysis |
6.2.2 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Ovarian Cancer, 2021- 2031F |
6.2.3 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Fallopian Tube Cancer, 2021- 2031F |
6.2.4 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Breast Cancer, 2021- 2031F |
6.2.5 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.3 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By End User |
6.3.1 Overview and Analysis |
6.3.2 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.3.3 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Homecare, 2021- 2031F |
6.3.4 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.3.5 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
6.4 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.4.3 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.4.4 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.4.5 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenues & Volume, By Others, 2021- 2031F |
7 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Import-Export Trade Statistics |
7.1 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Export to Major Countries |
7.2 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Imports from Major Countries |
8 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Key Performance Indicators |
8.1 Number of clinical trials of PARP inhibitors conducted in China |
8.2 Adoption rate of PARP inhibitors in cancer treatment in China |
8.3 Number of research publications on PARP inhibitors from Chinese institutions. |
9 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market - Opportunity Assessment |
9.1 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Opportunity Assessment, By Drugs Type, 2021 & 2031F |
9.2 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Opportunity Assessment, By Indication Type, 2021 & 2031F |
9.3 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Opportunity Assessment, By End User, 2021 & 2031F |
9.4 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market - Competitive Landscape |
10.1 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Revenue Share, By Companies, 2024 |
10.2 China Poly (ADP Ribose) Polymerase (PARP) Inhibitors Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here